{"id":140251,"title":"Avacta pays £2.61m bond instalment as debt falls to £12m","publisher":"Share Talk","author":"sharetalk","published":"2026-09-04T06:51:09+00:00","modified":"2026-09-04T06:56:05+00:00","canonical_url":"https://www.share-talk.com/avacta-pays-2-61m-bond-instalment-as-debt-falls-to-12m/","markdown_url":"https://www.share-talk.com/avacta-pays-2-61m-bond-instalment-as-debt-falls-to-12m.md","json_url":"https://www.share-talk.com/avacta-pays-2-61m-bond-instalment-as-debt-falls-to-12m.json","category":"Health","categories":["Health","Healthcare","Pharmaceutical"],"tags":["Abingdon Health","AffyXell Therapeutics","antigen","Avacta Group","AVCT","Biotherapeutics","Chris Yates","Christina Coughlin","clinical","COVID-19","Cytiva","Daewoong Pharmaceutical","diagnostic","Doncaster","Europe","LG Chem Life Sciences","Michelle Morrow","Pharma","radiopharmaceuticals","saliva test","SARS-COV-2","Sengho Jeon","Share Talk","South Korea","therapeutic","UK","validation","York"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2026/09/7c036f10-6f88-407f-ad49-bf9b978f047c.png?fit=1727%2C911&quality=80&ssl=1","format":"news","language":"en-GB","content":"[Avacta Therapeutics (AIM: AVCT)](https://www.investegate.co.uk/announcement/rns/avacta-group--avct/accelerated-payment-convertible-bond-installment/9755174)has settled an accelerated deferred convertible bond repayment of **£2.613 million in cash**, reducing the remaining principal under the facility to £12 million.\n\nThe payment relates to the April 2026 quarterly amortisation instalment and comprises **£2.4 million of principal plus associated interest and deferment fees**.\n\nAvacta said the bondholder issued an accelerated payment notice for the deferred instalment, with the company electing to settle the amount in cash rather than through conversion into shares.\n\nFollowing the payment, **both previously deferred quarterly repayments have now been satisfied**.\n\nTogether with the scheduled July 2026 repayment, which was also made in cash, the latest settlement reduces the outstanding convertible bond principal to **£12.0 million**.\n\nAvacta said the remaining principal now represents approximately **3.8% of the company’s market capitalisation**."}